A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants With Advanced Breast Cancer
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- EQRx, Inc.
- 入组人数
- 100
- 试验地点
- 42
- 主要终点
- Incidence of AEs and SAEs
研究概览
简要总结
This is a multicenter, single-arm, open-label study to evaluate the safety and efficacy of lerociclib in combination with standard endocrine therapy in female or male participants with HR+/HER2- MBC. The study population will consist of either newly diagnosed, treatment naïve participants with HR+/HER2- MBC (1L population) and participants with HR+/HER2- MBC who have already progressed on first line endocrine therapy such as tamoxifen, anastrozole, or letrozole (2L population). All premenopausal or perimenopausal female participants, and all male participants, must be receiving goserelin for at least 28 days prior to entering the study and will remain on goserelin throughout the study, in accordance with the prescribing information and according to the study site's standard practice.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must be 18 or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent.
- •Histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by local laboratory and has HER2-negative breast cancer.
- •Advanced (locoregionally recurrent not amenable to curative therapy, eg, surgery and/or radiotherapy, or metastatic) breast cancer
- •Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or
- •Adequate bone marrow and organ function
- •Female that is not pregnant and agrees to contraceptive use that is consistent with local regulations regarding the methods of contraception to be used during the study
- •Males agree to use a highly effective method of contraception and will refrain from donating sperm from the first dose of any study intervention
- •Participant is capable of giving signed informed consent
排除标准
- •Symptomatic visceral disease or any disease burden that makes the participant ineligible for endocrine therapy per the Investigator's best judgment.
- •Peritoneal carcinomatosis.
- •Inflammatory breast cancer at screening.
- •Participant with central nervous system (CNS) involvement unless they are at least 4 weeks from prior therapy completion to starting the study treatment and have stable CNS tumor at the time of screening and not receiving steroids and/or enzyme inducing anti-epileptic medications for brain metastases.
- •Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality
- •Has a history of prolonged QT syndrome or Torsades de Pointes
- •Has received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy) or any CDK4/6 inhibitor.
- •Has received prior treatment with fulvestrant.
- •Use of systemic estrogens
- •Participant is currently receiving any of the following substances and cannot be discontinued 14 days prior to start the treatment:
- •Known strong or moderate CYP3A inducers or strong inhibition of CYP3A
- •Substances that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/
- •Echocardiogram done within the past 12 months with ejection fraction of ≤ 45% or documented history of congestive heart failure with reduced ejection fraction.
- •Evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or oral temperature > 38°C at screening
- •Interstitial pneumonia or severe impairment of lung function
研究组 & 干预措施
Lerociclib + letrozole or fulvestrant
Letrozole, administered orally once daily in tablet form at 2.5 mg.
Fulvestrant, administered as an intramuscular injection, once every 2 weeks for the initial 3 doses and then once every 4 weeks (Q4W) thereafter, at 500 mg.
干预措施: Lerociclib + Letrozole or Fulvestrant (Drug)
结局指标
主要结局
Incidence of AEs and SAEs
时间窗: Up to 4.5 years
The number and percentage of participants experiencing any TEAE and serious TEAE will be tabulated by line of therapy.
次要结局
未报告次要终点